Novel immunotherapeutic approaches to prostate cancer

Current Opinion in Molecular Therapeutics

Volumn 7, Issue 1, 2005, Pages 30-34

  Dalgleish, Angus ^a   Whelan, Mike ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b Onyvax Ltd   (United Kingdom)

Author keywords

Dendritic cell; DNA; Immunotherapy; Peptide; Prostate cancer; Whole cell

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; BCG VACCINE; CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; DENDRITIC CELL VACCINE; DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 2; LEUKOCYTE ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELANOMA ANTIGEN; MUCIN 1; PROSTATE ANTIGEN; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE STEM CELL ANTIGEN; PROTEIN P53; PROTEOME; PROVENGE; TUMOR ANTIGEN; TUMOR CELL VACCINE; VIRUS VECTOR;

ANTIGEN SPECIFICITY; BLADDER CANCER; CANCER IMMUNOTHERAPY; CANCER STAGING; CELL LYSATE; CLINICAL TRIAL; EFFECTOR CELL; GENETIC TRANSFECTION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; MYELOID LEUKEMIA; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEIN TARGETING; REVIEW; T LYMPHOCYTE; TH1 CELL; VIRAL GENE DELIVERY SYSTEM;

ANTIGENS; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 14244258734     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Cancer Research UK: Cancer statistics. World Wide Web site (2004). http://www.cancerresearchuk.org/aboutcancer/statistics/incidence
2. Wiemann B, Starnes CO: Coley's toxins, tumor necrosis factor and cancer research: A historical perspective. Pharmacol Ther (1994) 64(3):529-564.
3. Burnet FM: Immunological aspects of malignant disease. Lancet (1967) 1(7501):1171-1174.
4. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD: Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol (2002) 3(11):991-998.
5. Meloni G, Trisolini SM, Capria S, Torelli GF, Baldacci E, Torromeo C, Valesini G, Mandelli F: How long can we give interleukin-2? Clinical and immunological evaluation of AML patients after 10 or more years of IL2 administration. Leukemia (2002) 16(10):2016-2018.
6. Bevers RF, Kurth KH, Schamhart DH: Role of urothelial cells in BCG immunotherapy for superficial bladder cancer. Br J Cancer (2004) 91(4):607-612.
7. Rivera P, Inostroza J, Treulen F: Intraprostatic BCG vaccine in patients with prostatic cancer. Expression of interferon γ and interieukin 4 (a preliminary study). Acta Urol Esp (2002) 26(5):351-355.
8. Hrouda D, Baban B, Dunsmuir WD, Kirby RS, Dalgleish AG: Immunotherapy of advanced prostate cancer: A phase VII trial using Mycobacterium vaccae (SRL172). Br J Urol (1998) 82 4):568-573.
9. Whelan M, Whelan J, Russell N, Dalgleish A: Cancer immumotherapy: An embarrassment of riches? Drug Discov Today (2003) 8(6):253-258.
10. Meidenbauer N, Gooding W, Spitler L, Harris D, Whiteside TL: Recovery of ζ-chain expression and changes in spontaneous IL-10 production after PSA-based vaccines in patients with prostate cancer. Br J Cancer (2002) 86(2):168-178.
11. Meidenbauer N, Harris DT, Spitler LE, Whiteside TL: Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate (2000) 43(2):88-100.
12. Kobayashi K, Noguchi M, Itoh K, Harada M: Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prostate cancer patients. Cancer Sci (2003) 94(7):622-627.
13. Lu J, Celis E: Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen Cancer Res (2002) 62(20):5807-5812.
14. McNeel DG, Nguyen LD, Disis ML: Identification of T helper epitopes from prostatic acid phosphatase. Cancer Res (2001) 61(13):5161-5167.
15. Matsueda S, Kobayashi K, Nonaka Y, Noguchi M, Itoh K, Harada M: Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2+ patients with hormone-refractory prostate cancer Cancer Immunol Immunother (2004) 53(6):479-489.
16. Matsueda S, Yao A, Ishihara Y, Ogata R, Noguchi M, Itoh K, Harada M: A prostate stem cell antigen-derived peptide immunogenic in HILA-A24-prostate cancer patients. Prostate (2004) 60 3):205-213.
17. Friedman RS, Spies AG, Kalos M: Identification of naturally processed CD8 T cell epitopes from prostein, a prostate tissue-specific vaccine candidate. Eur J Immunol (2004) 34 4):1091-1101.
18. Kiessling A, Schmitz M, Stevanovic S, Weigle B, Holig K, Fussell M, Fussel S, Meye A, Wirth MP, Rieber EP: Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients. Int J Cancer (2002) 102(4):390-397.
19. Kiessling A, Stevanovic S, Fussel S, Weigle B, Rieger MA, Temme A, Rieber EP, Schmitz M: Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein prostein. Br J Cancer (2004) 90 5):1034-1040.
20. Hural JA, Friedman RS, McNabb A, Steen SS, Henderson RA, Kalos M: Identification of naturally processed CD4 T cell epitopes from the prostate-specific antigen kallikrein 4 using peptide-based in vitro stimulation. J Immunol (2002) 169(1):557-565.
21. Schroers R, Shen L, Rollins L, Xiao Z, Sonderstrup G, Slawin K, Huang XF, Chen SY: Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen. Clin Cancer Res (2003) 9(9):3260-3271.
22. Chakraborty NG, Stevens RL, Mehrotra S, Laska E, Taxel P, Sporn JR, Schauer P, Albertsen PC: Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation. Cancer Immunol Immunother (2003) 52 8):497-505.
23. Noguchi M, Itoh K, Suekane S, Yao A, Suetsugu N, Katagiri K, Yamada A, Yamana H, Noda S: Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer. Cancer Sci (2004) 95 1):77-84.
24. Berlyn KA, Schultes B, Leveugle B, Noujaim AA, Alexander RB, Mann DL: Generation of CD4+ and CD8+ T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/antibody) complexes. Clin Immunol (2001) 101(3):276-283.
25. Lundqvist A, Choudhury A, Nagata T, Andersson T, Quinn G, Fong T, Maitland N, Pettersson S, Paulie S, Pisa P: Recombinant adenovirus vector activates and protects human monocyte-derived dendritic cells from apoptosis. Hum Gene Ther (2002) 13 13):1541-1549.
26. Kaufman HL, Wang W, Manola J, DiPaola RS, Ko YJ, Sweeney C, Whiteside TL, Schlom J, Wilding G, Weiner LM: Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): A trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2004) 22(11):2122-2132.
27. Steinman RM, Pope M: Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest (2002) 109(12 ):1519-1526.
28. Feuerstein B, Berger TG, Maczek C, Roder C, Schreiner D, Hirsch U, Haendle I, Leisgang W, Glaser A, Kuss O, Diepgen TL et al A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use. J Immunol Methods (2000) 245(1-2):15-29.
29. John J, Hutchinson J, Dalgleish A, Pandha H: Cryopreservation of immature monocyte-derived dendritic cells results in enhanced cell maturation but reduced endocytic activity and efficiency of adenoviral transduction. J Immunol Methods (2003) 272 1-2):35-48.
30. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH: Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol (2000) 18 23):3894-3903.
31. Valone FH, Small E, MacKenzie M, Burch P, Lacy M, Peshwa MV, Laus R: Dendritic cell-based treatment of cancer: Closing in on a cellular therapy. Cancer J (2001) 7(Suppl 2):S53-S61.
32. Burch PA, Croghan GA, Gastineau DA, Jones LA, Kaur JS, Kylstra JW, Richardson RL, Valone FH, Vuk-Pavlovic S: Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatese can induce durable remission of metastatic androgen-independent prostate cancer: A phase 2 trial. Prostate (2004) 60(3):197-204.
33. Gilboa E, Vieweg J: Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev (2004) 199 251-263.
34. Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, Dahm P, Niedzwiecki D, Gilboa E, Vieweg J: Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest (2002) 109(3):409-417.
35. Fong L, Brockstedt D, Benike C, Breen JK, Strang G, Ruegg CL, Engleman EG: Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol (2001) 167(12 ):7150-7156.
36. Fong L, Brockstedt D, Benike C, Wu L, Engleman EG: Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol (2001) 166(6):4254-4259.
37. Pandha HS, John RJ, Hutchinson J, James N, Whelan M, Corbishley C, Dalgleish AG: Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: A phase I/II study. BJU Int (2004) 94(3 ):412-418.
38. Jocham D, Richter A, Hoffmann L, Iwig K, Fahlenkamp D, Zakrzewski G, Schmitt E, Dannenberg T, Lehmacher W, von Wietersheim J, Doehn C: Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial. Lancet (2004) 363(9409):594-599.
39. Dummer R: GVAX (Cell Genesys). Curr Opin Investig Drugs (2001) 2(6):844-848.
40. Todryk SM, Eaton J, Birchall L, Greenhalgh R, Soars D, Dalgleish AG, Melcher AA, Pandha HS: Heated tumour cells of autologous and allogeneic origin elicit anti-tumour immunity. Cancer Immunol Immunother (2004) 53(4):323-330.
41. Eaton JD, Perry MJ, Nicholson S, Guckian M, Russell N, Whelan M, Kirby RS: Allogeneic whole-cell vaccine: A phase I/II study in men with hormone-refractory prostate cancer. BJU Int (2002) 89 1):19-26.
42. Pandha HS, Michael A, Quata, Wushishi F, Russell N, Whelan J, Whelan M: The effect of whole cell allogensic vaccination on the progression of hormone-relapsed prostate cancer. J Clin Oncol (2004) 22(9):4735-4735.
43. Oikawa T, Kawai K, Ishiwata I, Ohno T Akaza H: Induction of potent antitumour natural-killer cells from peripheral blood of patients with advanced prostate cancer. BJU Int (2003) 92 3):1009-1015.
44. Wajchman HJ, Pierce CW, Varma VA, Issa MM, Petros J, Dombrowski KE: Ex vivo expansion of CD8+CD56+ and CD8+CD56- natural killer T cells specific for MUC1 mucin. Cancer Res (2004) 64(4):1171-1180.
45. Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K, Plymate SR: Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest (2004) 114(4):560-568.